Trials / Conditions / Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
5 registered clinical trials studyying Ann Arbor Stage III Marginal Zone Lymphoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma NCT06442475 | University of Washington | Phase 2 |
| Active Not Recruiting | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Ly NCT04323956 | Mayo Clinic | Phase 1 |
| Completed | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage NCT02532257 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lym NCT00695786 | M.D. Anderson Cancer Center | Phase 2 |